Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + DC-NK cell therapy
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Pembrolizumab + DC-NK cell therapy is a combination investigational immunotherapy regimen comprising pembrolizumab, a programmed cell death-1 (PD-1) inhibitor monoclonal antibody, with dendritic cell–natural killer (DC-NK) cell therapy. The mechanism relies on pembrolizumab’s blockade of PD-1 to release T cell and NK cell activity, while DC-NK cell therapy introduces either autologous or allogeneic cytotoxic NK cells often primed or expanded ex vivo (sometimes with support from dendritic cells) to directly enhance antitumor immune responses. This strategy aims to improve antitumor efficacy via both checkpoint inhibition and cellular immunotherapy, targeting challenging malignancies such as advanced non–small cell lung cancer (NSCLC) and biliary tract cancer[1][2][3].
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + DC-NK cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + DC-NK cell therapy.